Whole Brain Radiation Therapy With Local Simultaneous Integrated Boost Conformal Radiation Therapy in the Treatment for Patients With 1-3 Brain Metastases

of rCBV, rCBF, and rK2trans identified cut-off values with optimal sensitivity and specificity for outcome. Results: rK2trans distinguished PD from response (p Z 0.03). The optimal threshold value, sensitivity, specificity and AUC were 12.8, 69.2%, 63.6% and 67.4%, respectively. rCBF and rCBV at one month discriminated PD from non-PD (p < 0.05 each) with optimal threshold values, sensitivity, specificity and AUC of 2.09, 87.5%, 66.7%, 74.2% and 3.08, 82.8%, 81.8%, 84.3%, respectively. Logistic regression identified decreased rK2trans, absence of prior radiation and steroid administration at one week as early predictors of tumor response (complete or partial response). At one month, only a decrease in rCBV was predictive OF PD. Conclusions: Early changes in rK2trans and rCBV are biomarkers of therapeutic response for brain metastases following radiation. Author Disclosure: A. Sahgal: None. R. Jakubovic: None. R. Milwid: None. A. Eilaghi: None. H. Soliman: None. R.I. Aviv: None.